These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [New therapies for urologic cancer diseases. The Danish Society of Urology]. Lund L; Borre M; Hermann GG; Svolgaard N; Ugeskr Laeger; 2008 Mar; 170(12):1057. PubMed ID: 18397675 [No Abstract] [Full Text] [Related]
43. Advances in urologic oncology "OncoForum": The best of 2019. Gómez-Veiga F; Alcaraz Asensio A; Burgos Revilla J; Cózar Olmo J Actas Urol Esp (Engl Ed); 2020 Nov; 44(9):586-596. PubMed ID: 32948345 [TBL] [Abstract][Full Text] [Related]
48. Comparative effectiveness research in urologic cancers. Strope SA Cancer Treat Res; 2015; 164():221-35. PubMed ID: 25677026 [TBL] [Abstract][Full Text] [Related]
49. Present status of cancer treatment in Singapore-management of urological cancers. Tun KH; Tan EC; Foo KT Gan To Kagaku Ryoho; 1992 Jul; 19(8 Suppl):1139-45. PubMed ID: 1514826 [No Abstract] [Full Text] [Related]
50. [Clinical efficacy of interferon-beta (MR-21) in renal cell carcinoma and cancer of the bladder]. Niijima T Nihon Gan Chiryo Gakkai Shi; 1987 Jun; 22(5):928-33. PubMed ID: 3694001 [No Abstract] [Full Text] [Related]
51. [Are therapeutics decisions homogeneous in multidisciplinary onco-urology staff meeting? Comparison of therapeutic options taken in four departments from Paris]. Audenet F; Lejay V; Mejean A; De La Taille A; Abbou CC; Lebret T; Botto H; Bitker MO; Roupret M Prog Urol; 2012 Jun; 22(7):433-7. PubMed ID: 22657264 [TBL] [Abstract][Full Text] [Related]
52. Trends in palliative care interventions among patients with advanced bladder, prostate, or kidney cancer: A retrospective cohort study. Lec PM; Lenis AT; Brisbane W; Sharma V; Golla V; Gollapudi K; Blumberg J; Drakaki A; Bergman J; Chamie K Urol Oncol; 2020 Nov; 38(11):854.e1-854.e9. PubMed ID: 32430252 [TBL] [Abstract][Full Text] [Related]
53. [Utility of the serum CRP value for assessing the prognosis and therapeutic response of urological malignancies]. Köhler A; Eggers H; Kuczyk MA; Schrader AJ; Steffens S Aktuelle Urol; 2013 Nov; 44(6):452-5. PubMed ID: 24258396 [TBL] [Abstract][Full Text] [Related]
54. [Update urooncology: news with clinical relevance from major scientific meetings 2012]. Hegele A; Skrobek L; Schrader AJ Aktuelle Urol; 2012 Dec; 43(6):376-87. PubMed ID: 23254351 [TBL] [Abstract][Full Text] [Related]
55. Genitourinary small cell carcinoma: determination of clinical and therapeutic factors associated with survival. Mackey JR; Au HJ; Hugh J; Venner P J Urol; 1998 May; 159(5):1624-9. PubMed ID: 9554367 [TBL] [Abstract][Full Text] [Related]
56. Evolving immunotherapeutic strategies in bladder and renal cancer. Griffiths TR; Mellon JK Postgrad Med J; 2004 Jun; 80(944):320-7. PubMed ID: 15192163 [TBL] [Abstract][Full Text] [Related]
57. New developments in the use of monoclonal antibodies in the therapy of genitourinary cancer. Lampe MI; Oosterwijk E BJU Int; 2000 Jul; 86(2):165-71;quiz i-ii. PubMed ID: 10886103 [No Abstract] [Full Text] [Related]
58. [News with clinical relevance from major scientific meetings 2014 - Update Urooncology]. Hegele A; Skrobek L; Boegemann M Aktuelle Urol; 2015 Mar; 46(2):106-17. PubMed ID: 25909966 [TBL] [Abstract][Full Text] [Related]